{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:44:26Z","timestamp":1792082666571,"version":"4.4.0"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:p>Chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) is a low-grade B-cell neoplasm and \u223c2% to 9% patients develop an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (Richter transformation, DLBCL-RT). Programmed death-1 (PD-1) pathway plays a crucial role in tumor host immunity evasion and its blockade has emerged as an effective anti-cancer immunotherapy. PD-L1 and PD-1 expression has shown predictive value in anti-PD cancer immunotherapy; however, it has not been well documented in CLL\/SLL and DLBCL-RT. We evaluated PD-1 and PD-L1 expression by immunohistochemistry in 39 CLL\/SLL, 15 DLBCL-RT, and 26 other DLBCL. In CLL\/SLL, neoplastic B-cell PD-1 expression was weak and restricted to prolymphocytes\/paraimmunoblasts within proliferation centers (PCs) and accentuated PCs of all sizes. Neoplastic B-cell PD-1 expression was highly prevalent and demonstrated increased intensity in DLBCL-RT, but in contrast was only rarely seen in other DLBCL (12\/15 vs. 1\/26; <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001). An excellent correlation (90% concordance) was observed between neoplastic B-cell PD-1 immunohistochemistry positivity and molecularly defined CLL\/SLL clonal relatedness in DLBCL-RT. PD-L1 expression was observed on the neoplastic B cells in rare DLBCL-RT and other DLBCL cases (1\/15 vs. 1\/26; <jats:italic toggle=\"yes\">P<\/jats:italic>&gt;0.05) as well as background histiocytes and dendritic cells. Overall survival of DLBCL-RT was significantly inferior to that of the other DLBCL (median, 16.9 vs. 106.1\u2009mo; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.002). Our findings suggest a biological continuum from prolymphocytes\/paraimmunoblasts in CLL\/SLL PCs to the neoplastic B-cells in DLBCL-RT. The characteristic PD-1 expression in DLBCL-RT makes it a potential surrogate marker for determining clonal relatedness to CLL\/SLL, which may have important prognostic and therapeutic implications.<\/jats:p>","DOI":"10.1097\/pas.0000000000001077","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T22:04:14Z","timestamp":1526421854000},"page":"843-854","source":"Crossref","is-referenced-by-count":79,"title":["PD-1 Expression in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL) and Large B-cell Richter Transformation (DLBCL-RT)"],"prefix":"10.1097","volume":"42","author":[{"given":"Rong","family":"He","sequence":"first","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[{"name":"Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Viswanatha","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shi","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Van Dyke","sequence":"additional","affiliation":[{"name":"Laboratory Genetics and Genomics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulan","family":"Tian","sequence":"additional","affiliation":[{"name":"Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda N.","family":"Dao","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tait D.","family":"Shanafelt","sequence":"additional","affiliation":[{"name":"Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Call","sequence":"additional","affiliation":[{"name":"Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F.","family":"Leis","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic College of Medicine, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Mai","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Rech","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2011-07-370403","article-title":"Surface IgM stimulation induces MEK1\/2-dependent MYC expression in chronic lymphocytic leukemia cells","volume":"119","author":"Krysov","year":"2012","journal-title":"Blood"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cncr.20773","article-title":"Richter syndrome: biology, incidence, and therapeutic strategies","volume":"103","author":"Tsimberidou","year":"2005","journal-title":"Cancer"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1993.11.10.1985","article-title":"Richter\u2019s syndrome: a report on 39 patients","volume":"11","author":"Robertson","year":"1993","journal-title":"J Clin Oncol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00130404-200505000-00001","article-title":"Richter\u2019s syndrome: biology and therapy","volume":"11","author":"Yee","year":"2005","journal-title":"Cancer J"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/10428190290016872","article-title":"Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter\u2019s syndrome or refractory lymphoproliferative disorders","volume":"43","author":"Tsimberidou","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"R24-20230922","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2015-02-626754","article-title":"Mechanisms of PD-L1\/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Emicro-TCL1 CLL mouse model","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with chronic lymphocytic leukemia with Richter\u2019s transformation and relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00019606-199203000-00037","article-title":"Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues","volume":"1","author":"Chang","year":"1992","journal-title":"Diagn Mol Pathol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","article-title":"Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma","volume":"30","author":"Dorfman","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.humpath.2007.11.012","article-title":"Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma\/chronic lymphocytic leukemia","volume":"39","author":"Xerri","year":"2008","journal-title":"Hum Pathol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1155\/2010\/404069","article-title":"Diagnostic and prognostic utility of PD-1 in B cell lymphomas","volume":"29","author":"Muenst","year":"2010","journal-title":"Dis Markers"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"e35178","DOI":"10.1371\/journal.pone.0035178","article-title":"Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia","volume":"7","author":"Grzywnowicz","year":"2012","journal-title":"PLoS One"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3324\/haematol.2010.022277","article-title":"Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\u201caccelerated\u201d chronic lymphocytic leukemia) with aggressive clinical behavior","volume":"95","author":"Gine","year":"2010","journal-title":"Haematologica"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/leu.2011.247","article-title":"Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays","volume":"26","author":"Ciccone","year":"2012","journal-title":"Leukemia"},{"key":"R41-20230922","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"key":"R42-20230922","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1309\/AJCPIVKZRMPF93ET","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression","volume":"138","author":"Gradowski","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"R43-20230922","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/bjh.13844","article-title":"Proliferation centres of chronic lymphocytic leukaemia\/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene","volume":"175","author":"Gibson","year":"2015","journal-title":"Br J Haematol"},{"key":"R44-20230922","doi-asserted-by":"crossref","first-page":"63","DOI":"10.7326\/0003-4819-119-1-199307010-00011","article-title":"Genetic relatedness of lymphoid malignancies. Transformation of chronic lymphocytic leukemia as a model","volume":"119","author":"Foon","year":"1993","journal-title":"Ann Intern Med"},{"key":"R45-20230922","first-page":"207","article-title":"De novo CD5-positive and Richter\u2019s syndrome-associated diffuse large B cell lymphomas are genotypically distinct","volume":"147","author":"Matolcsy","year":"1995","journal-title":"Am J Pathol"},{"key":"R46-20230922","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1309\/RM1Q-1T0B-WKQB-AF5A","article-title":"De novo CD5+ diffuse large B-cell lymphomas. A heterogeneous group containing an unusual form of splenic lymphoma","volume":"114","author":"Kroft","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"R47-20230922","first-page":"722","article-title":"Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study","volume":"9","author":"Linderoth","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R48-20230922","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter\u2019s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R49-20230922","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/leu.2009.285","article-title":"Proliferation centers in chronic lymphocytic leukemia: the niche where NF-kappaB activation takes place","volume":"24","author":"Herreros","year":"2010","journal-title":"Leukemia"},{"key":"R50-20230922","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.semcancer.2010.08.004","article-title":"The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia","volume":"20","author":"Packham","year":"2010","journal-title":"Semin Cancer Biol"},{"key":"R51-20230922","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/blood-2017-02-766857","article-title":"Large B-cell lymphoma variant of Richter transformation originates in pseudoproliferation centers of small lymphocytic lymphoma","volume":"129","author":"Wang","year":"2017","journal-title":"Blood"},{"key":"R52-20230922","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"R53-20230922","doi-asserted-by":"crossref","first-page":"328rv324","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"R54-20230922","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"R55-20230922","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"R56-20230922","doi-asserted-by":"crossref","first-page":"e6398","DOI":"10.1097\/MD.0000000000006398","article-title":"The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma","volume":"96","author":"Fang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R57-20230922","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R58-20230922","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R59-20230922","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5414\/NP300698","article-title":"PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)","volume":"33","author":"Berghoff","year":"2014","journal-title":"Clin Neuropathol"},{"key":"R60-20230922","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hon.2375","article-title":"PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival","volume":"35","author":"Four","year":"2017","journal-title":"Hematol Oncol"},{"key":"R61-20230922","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","article-title":"Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas","volume":"54","author":"Menter","year":"2016","journal-title":"Hum Pathol"},{"key":"R62-20230922","first-page":"58","article-title":"Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies","volume":"1865","author":"Xia","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"R63-20230922","doi-asserted-by":"crossref","first-page":"59976","DOI":"10.18632\/oncotarget.11045","article-title":"PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications","volume":"7","author":"Xing","year":"2016","journal-title":"Oncotarget"},{"key":"R64-20230922","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/his.12882","article-title":"Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas","volume":"68","author":"Kwon","year":"2016","journal-title":"Histopathology"},{"key":"R65-20230922","doi-asserted-by":"crossref","first-page":"44960","DOI":"10.18632\/oncotarget.16680","article-title":"Mechanisms of PD-1\/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies","volume":"8","author":"Gravelle","year":"2017","journal-title":"Oncotarget"},{"key":"R66-20230922","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201807000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:49:03Z","timestamp":1695422943000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201807000-00001"}},"subtitle":["A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness"],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001077","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}